Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

KALEIDO BIOSCIENCES, INC.

(KLDO)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
Business Summary
Logo Kaleido Biosciences, Inc.
Kaleido Biosciences, Inc. is a clinical-stage healthcare company focused on leveraging the potential of the microbiome organ to treat disease and improve human health. Its Microbiome Metabolic Therapies (MMTs) is designed to drive the function and distribution of the microbiomes existing microbes in order to decrease or increase the production of metabolites to certain bacteria in the microbiome community. The Company is also advancing a broad pipeline of MMT candidates with the potential to address a variety of diseases and conditions with unmet patient needs. The Company utilizes its discovery and development platform to study MMTs in microbiome samples to rapidly advance MMT candidates into clinical studies in healthy subjects and patients. Its KB195 is the lead MMT candidate for development in the treatment of patients with urea cycle disorders. The Company is conducting a Phase II clinical trial under an Investigational New Drug Application (IND).

Number of employees : 82 people.
Managers
Name Title Age Since
Daniel L. Menichella President, Chief Executive Officer & Director 61 2020
William E. Duke Chief Financial Officer 48 -
Johan van Hylckama Vlieg, Dr. Chief Scientific Officer 52 2019
Kimberly Hocknell Senior Vice President-Technical Operations - -
Alison Long, Dr. Chief Medical Officer - 2021
Jerald Korn Chief Operating Officer & General Counsel 42 -
Bonnie L. Bassler, Dr. Independent Director 59 2018
R. Grady Burnett Independent Director 48 2018
Anthony G. Quinn, Dr. Independent Director 59 2016
Theo Melas-Kyriazi Chairman 61 2021
Members of the board
Name Title Age Since
Theo Melas-Kyriazi Chairman 61 2021
Geoffrey von Maltzahn, Dr. Chief Executive Officer 40 2015
Bonnie L. Bassler, Dr. Independent Director 59 2018
R. Grady Burnett Independent Director 48 2018
Anthony G. Quinn, Dr. Independent Director 59 2016
Jean K. Mixer Independent Director 54 2019
Anne Prener, Dr. Independent Director 63 2020
Daniel L. Menichella President, Chief Executive Officer & Director 61 2020
Equities
Vote QuantityFree-FloatCompany-owned sharesTotal Float
Stock A 1 42,594,350 38,753,540 91.0% 0 0.0% 91.0%
Shareholders
NameEquities%
Flagship Pioneering 19,575,710 46.0%
Fidelity Management & Research Co. LLC 3,693,930 8.67%
HarbourVest Partners LLC 1,833,832 4.31%
Michael Bonney 1,579,676 3.71%
The Vanguard Group, Inc. 993,183 2.33%
Federated Global Investment Management Corp. 825,000 1.94%
Palo Alto Investors LP 786,400 1.85%
Baillie Gifford & Co. 721,512 1.69%
Invus Public Equities Advisors LLC 500,500 1.18%
SSgA Funds Management, Inc. 443,804 1.04%
Company contact information
Kaleido Biosciences, Inc.
65 Hayden Avenue
Lexington, MA 02421

Phone : +1.617.674.9000
Web : http://www.kaleido.com
Brand Portfolio
In partnership withAllbrands.markets
More brands of Kaleido Biosciences, Inc.